Literature DB >> 17387558

Ciprofloxacin penetration into the pulmonary parenchyma in Japanese patients.

Shuji Haraguchi1, Masafumi Hioki, Koji Yamashita, Koan Orii, Yasuo Yamashita, Jun Kawamura, Mina Takushima, Naoya Endo, Kiyoshi Koizumi, Kazuo Shimizu.   

Abstract

PURPOSE: To assess the degree of penetration of intravenous (i.v.) ciprofloxacin into the lung parenchyma resected for lung carcinoma in Japanese patients.
METHODS: Ciprofloxacin was given i.v. over 1 h to ten Japanese patients with non-small cell lung carcinoma. We took 1 g of normal lung parenchyma and 1 ml of blood serum for analysis when the lung was resected. Ciprofloxacin concentrations were determined by high-performance liquid chromatography.
RESULTS: The mean time from the end of ciprofloxacin administration to lung resection was 135 +/- 55 min (range, 75-223 min). The mean concentrations of ciprofloxacin in the lung parenchyma and blood serum were 4.9 +/- 2.0 microg/g (range, 2.1-7.9) and 1.5 +/- 0.7 microg/ml (range, 0.8-2.7). The mean tissue per serum concentration ratio was 3.6 +/- 2.2 (range, 1.9-8.7).
CONCLUSION: The concentrations of ciprofloxacin in the lung parenchyma after i.v. administration in Japanese patients were above the minimal inhibitory concentration for bacteria from at least 75 min until 4 h later.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17387558     DOI: 10.1007/s00595-006-3393-4

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  6 in total

1.  Respiratory tract penetration of ciprofloxacin.

Authors:  T M Reid; I M Gould; D Golder; J S Legge; J G Douglas; J A Friend; S J Watt
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

2.  Concentration of ciprofloxacin in human serum, lung and pleural tissues and fluids during and after lung surgery.

Authors:  G Hopf; R Böcker; C J Estler; H J Radtke; W Floh
Journal:  Infection       Date:  1988       Impact factor: 3.553

3.  Penetration of ciprofloxacin into human lung tissue following intravenous injection.

Authors:  D Schlenkhoff; A Dalhoff; J Knopf; W Opferkuch
Journal:  Infection       Date:  1986 Nov-Dec       Impact factor: 3.553

4.  Evaluation of the penetration of ciprofloxacin and amoxycillin into the bronchial mucosa.

Authors:  D Honeybourne; J M Andrews; J P Ashby; R Lodwick; R Wise
Journal:  Thorax       Date:  1988-09       Impact factor: 9.139

5.  The penetration of ciprofloxacin into bronchial mucosa, lung parenchyma, and pleural tissue after intravenous administration.

Authors:  M Dan; K Torossian; D Weissberg; R Kitzes
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  [Nationwide sensitivity surveillance of ciprofloxacin and various parenteral antibiotics against bacteria isolated from patients with severe infections--the first Ciproxan IV special investigation in 2001].

Authors:  Keizo Yamaguchi; Yoshikazu Ishii; Yoshitsugu Iinuma; Kiyoharu Yamanaka; Satoshi Ichiyama; Naoki Watanabe; Nobuyuki Uehara; Mitsuo Kaku; Yukinori Kurokawa; Mutsumu Hayashi; Yoichi Hirakata
Journal:  Jpn J Antibiot       Date:  2003-12
  6 in total
  2 in total

1.  Predictors of atelectasis after pulmonary lobectomy.

Authors:  Alan J Stolz; Jan Schutzner; Robert Lischke; Jan Simonek; Tomas Harustiak; Pavel Pafko
Journal:  Surg Today       Date:  2008-10-29       Impact factor: 2.549

2.  Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC.

Authors:  Tomasz Kloskowski; Natalia Gurtowska; Joanna Olkowska; Jakub Marcin Nowak; Jan Adamowicz; Jakub Tworkiewicz; Robert Dębski; Alina Grzanka; Tomasz Drewa
Journal:  Int J Oncol       Date:  2012-10-04       Impact factor: 5.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.